“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology

On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR).

The approval of ONPATTRO™ has opened the door to a new era of gene therapies to treat most human diseases—including hereditary diseases, infectious diseases, chronic diseases and cancer—more effectively.

“It is just a matter of time.” This is the implication of a commentary published in the December 2019 issue of Nature Nanotechnology by the scientists and pharmaceutical experts behind the development of ONPATTRO™.

The senior author of the commentary is NMIN Scientific Director and CEO Dr. Pieter Cullis, whose laboratory contributed to the revolutionary lipid nanoparticle (LNP) delivery technology behind ONPATTRO’s success.

Read the press release.